HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Capricor Therapeutics (NASDAQ:CAPR) and raises the price target from $18 to $40.
October 04, 2023 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics' price target has been raised from $18 to $40 by HC Wainwright & Co.
The raised price target by HC Wainwright & Co. indicates a positive outlook for Capricor Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100